Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility.

Paschalis, Alec;Tombal, Bertrand;de Bono, Johann S
(2021) European Urology Focus — Vol. 7, n° 2, p. 231-233 (2021)

Files

Paschalis-2021inpress-Prostate-specificmembrane.pdf
  • Open Access
  • Adobe PDF
  • 192.72 KB
Download
Paschalis-2021-Prostate-specificmembrane.pdf
  • Open Access
  • Adobe PDF
  • 172.07 KB
Download

Details

Authors
Abstract
Prostate-specific membrane antigen-based theranostics are likely to become important tools for the management of prostate cancer. However, data proving their clinical utility are urgently required before implementation of their use outside clinical trials, and their off-trial use needs to be better regulated.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Paschalis, A., Tombal, B., & de Bono, J. S. (2021). Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility. European Urology Focus, 7(2), 231-233. https://doi.org/10.1016/j.euf.2021.01.009 (Original work published 2021)